<DOC>
	<DOCNO>NCT01008358</DOCNO>
	<brief_summary>CP-675,206 ( tremelimumab ) fully humanize monoclonal antibody bind activate T lymphocytes enhance activation may produce stimulation immune response tumoral viral antigen . In clinical trial , ability tremelimumab produce tumor response among hepatitis C virus-infected patient hepatocellular carcinoma amenable therapy explore . Besides , effect replication virus analyse .</brief_summary>
	<brief_title>Anti-CTLA-4 Human Monoclonal Antibody CP-675,206 Patients With Advanced Hepatocellular Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Tremelimumab</mesh_term>
	<criteria>Unequivocal diagnosis HCC unresectable disease amenable locoregional treatment . 4week washout period sorafenib systemic agent 2month washout period internal external radiation HCV chronic infection ChildPugh stage A B Measurable disease accord RECIST criterion ECOG &lt; 2 expect survival &gt; 3 month Adequate liver , renal blood function ability sign inform consent previous treatment antiCTL4 agent serious infection disease compromise general health status autoimmune disease require therapy treatment immunosuppressor treatment investigational agent neoplasms except skin bladder superficial tumor pregnancy lactation SNC metastasis HIV infection relevant heart disease ( NYHA class III IV )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
</DOC>